Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

NCT00427427 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

75

Enrollment

OTHER

Sponsor class

Stopped lack of accrual

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab

Sponsor

Jonsson Comprehensive Cancer Center